PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 105 | 40-50
Article title

Use of Traditional Japanese Medicine Kampo in course of Alzheimer’s Disease

Content
Title variants
Languages of publication
EN
Abstracts
EN
Dementia, the plague of the aging populations, is highly prevalent in East Asia, with currently over 9,8 million dementia patients. Alzheimer’s disease (AD), the most common cause of dementia, awaits for more detailed research in terms of understanding patomechanism of the disease, but more importantly, in supporting the treatment of this incurable disease in modern medicine. Therefore, alternative therapies assisting traditional therapeutic options become more popular, with the comeback of traditional medications, such as Traditional Japnese Medicine (TJM) - Kampo. The aim of this study was to present the use and effectiveness of TJM in treatment of symptoms of AD. Among articles in PubMed Medline database in years 2008-2018, 8 articles were selected for further analysis. Most of the research (38%) consisted of observational studies using different neuropsychiatric scales and methods of assessment of dementia. Studies presented significant improvements of behavioral symptoms with additional therapy with Yokukansan, Orengedoku-to, Ninjin’yoeito and other Kampo formulas in AD patients. Reviewed research presents effectiveness of Kampo treatment in supporting of cognitive and behavioral symptoms reduction, as well as protection of beta-amyloid induced toxicity. However, more research involving bigger cohorts is needed in order to confirm results on the larger scale, in order to introduce the beneficial aspects of Kampo in AD populations worldwide.
Discipline
Year
Volume
105
Pages
40-50
Physical description
Contributors
  • Student, I Faculty of Medicine, Medical University of Lublin, Al. Raclawickie 1, 20-059 Lublin, Poland
  • Pediatric Neurology Department, III Chair of Pediatrics, Medical University of Lublin, ul.Prof. A. Gebali 6, 20-093 Lublin, Poland
References
  • [1] Cunningham EL, McGuinness B, Herron B, Passmore AP. Dementia. Ulster Med J. (2015) May; 84(2): 79-87.
  • [2] Ferencz B, Gerritsen L. Genetics and Underlying Pathology of Dementia. Neuropsychol Rev. (2015); 25(1): 113–24.
  • [3] Duyckaerts C, Delatour B, Potier M. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. (2009) Jul; 118(1): 5-36.
  • [4] Wisniewski T, Frangione B Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. (1992) 135 (2): 235–8.
  • [5] Chouraki V, Seshadri S. Genetics of Alzheimer's Disease. Adv Genet. (2014) 87: 245–94.
  • [6] Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. (2011) 7, 137–152.
  • [7] Goedert M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. (2015) Aug 7; 349(6248): 1255555.
  • [8] Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. (2016) Apr; 12(4): 459-509.
  • [9] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Demen. (2011) 7(3): 263–9
  • [10] Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 353(22): 2335–41.
  • [11] Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA (2005) 294(15): 1934–43.
  • [12] Randel S, Soong LL. Traditional Chinese medicine in China. West J Med. (1983) Aug; 139(2): 236–238
  • [13] Latif A. Traditional Chinese medicine. J Pak Med Assoc. (1979) Feb; 29(2): 41-3.
  • [14] Katayama K, Yoshino T, Munakata K, Yamaguchi R, Imoto S et al. Prescription of Kampo Drugs in the Japanese Health Care Insurance Program. J Evid Based Complementary Altern Med (2013): 576973.
  • [15] Nikkei Medical, October 2000 (Supplement) (original in Japanese)
  • [16] Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K et al. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34: 541–545
  • [17] Okamoto H, Chino A, Hirasaki Y, Ueda K, Iyo M. et al. Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae. Neuropsychiatr Dis Treat (2013) :9 151–155
  • [18] Furukawa K, Tomita N, Uematsu D, Okahara K, Shimada H et al. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. Geriatr Gerontol Int. (2017) Feb; 17(2): 211-218.
  • [19] Okamoto H. Reconsideration of Japanese traditional herbal medicine: new field of research and clinical medicine. Mini Rev Med Chem. (2006) 6(5): 543–547.
  • [20] Kudoh C, Arita R, Honda M, Kishi T, Komatsu Y et al. Effect of ninjin’yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer’s disease: 2 years of observation. Psychogeriatrics. (2016) 16: 85–92
  • [21] Niitsu T, Okamoto H, Iyo M. Behavioural and psychological symptoms of dementia in an Alzheimer’s disease case successfully treated with natural medicine: association with gonadotropins. Psychogeriatrics. (2013) 13: 124–127
  • [22] Tohda, C., Naito, R., and Joyashiki, E. Kihi-to, a herbal traditional medicine, improves Abeta(25–35)- induced memory impairment and losses of neurites and synapses. BMC Complement. Altern. Med. (2008). 8, 49. doi: 10.1186/1472-6882-8-49.
  • [23] Tohda C, Nakada R, Urano T, Okonogi A, Kuboyama T. Kamikihi-to (KKT) Rescues Axonal and Synaptic Degeneration Associated with Memory Impairment in a Mouse Model of Alzheimer's Disease, 5XFAD. Int J Neurosci (2011) 121: 641–648
  • [24] Terasawa K, Shimada Y, Kita T, Yamamoto T, Tosa H. Choto-san in the treatment of vascular dementia: a double-blindplacebo-controlled study. Phytomedicine (1997) 4: 15–22.
  • [25] Wei M,, Chen L, Liu J, Zhao J, Liu W. et al. Protective effects of a Chotosan Fraction and its active components on beta-amyloid-induced neurotoxicity. Neurosci Lett (2016) 617: 143–149
  • [26] Yoshioka T, Murakami K, Ido K, Hanaki M, Yamaguchi K. et al. Semisynthesis and Structure−Activity Studies of Uncarinic Acid C Isolated from Uncaria rhynchophylla as a Specific Inhibitor of the Nucleation Phase in Amyloid β42. Aggregation J. Nat. Prod. (2016) 79: 2521−2529
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-3bee625d-baa0-413c-b6dd-182252eabfa8
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.